Formulation and In-vitro Evaluation of Gliclazide and Nimodipine Bilayer Tablets for the Treatment of Type II Diabetes Mellitus and Hypertension

Abstract

Background: In today's world, type 2 diabetes mellitus, and hypertension have become universal, and a large number of patients are living with diabetes mellitus and hypertension, which often coexist. The core idea of this study was the development of bilayer tablets collected from two unlike categories of drugs through a straightforward and easy-to-scale-up approach.
 Objective: In the present investigation, a bilayer tablet of Gliclazide and Nimodipine was developed to enhance long-suffering patient compliance. The objective of the current investigation was to develop a bilayer dosage form of Gliclazide and Nimodipine for oral route of administration that will liberate Nimodipine immediately and Gliclazide for 12 hrs. to increase the oral bioavailability of the drug.
 Methodology: The immediate-release (IR) sheet was developed by a variety of super-disintegrants like Crospovidone, Croscarmellose sodium, and sodium starch glycolate, and the sustained-release (SR) sheet was developed by a variety of polymers like Hydroxy Propyl Methyl Cellulose (HPMC), Hydroxy Propyl Cellulose (HPC), and Eudragit. Initially, the Gliclazide sheet was positioned in the die cavity and compacted. Then Nimodipine sheet was placed in the die cavity and compacted with a most favourable hardness of 6–8 kg/cm2 to get bilayer tablets.
 Results and Discussion: The in-vitro drug release of Nimodipine was 97% in 30 minutes and Gliclazide was 98% in 12 hours. The drug release of Gliclazide was only 4.7% in the first 30 minutes; it showed that drug release of Gliclazide was negligible up to 30 minutes. The addition of sodium lauryl sulfate to the (IR) sheet and dissolution medium (SR) improved the drug release from both sheets. 
 Conclusion: The current research concluded that the selected bilayer tablet was found good to treat diabetes mellitus and hypertension by the chronological release of both drugs from a developed bilayer tablet. Also, this bilayer tablet reduces the dosage frequency.